Technologies (IVT) signed an agreement with the La Jolla Institute
for Allergy & Immunology to test the application of its DepoVax
™ vaccine delivery system for influenza
and arenavirus vaccines.
The institute’s epitope-based vaccines are in preclinical research. The goal is that using DepoVax, only one vaccine dose will be required for protective immunity and that a strong cellular and humoral response is achieved.
DepoVax uses liposomes to encapsulate a target antigen and adjuvant. The vaccine formulation also relies on a hydrophobic oil carrier. The result is a depot effect that enhances vaccine induced cell-mediated and humoral immunity, according to IVT.